Description

EpiCept™ MP/DP is a spray gel matrix of morphine and lidocaine for the treatment of oral mucositis and dental pain. A spray gel matrix is a liquid spray that solidifies upon contact with a warm surface. Oral mucositis is an inflammation of the mucosa of the mouth that ranges from redness to severe ulceration, which are typically side effects from chemical and radiation therapies. Approximately 400,000 U.S. cancer patients suffer from oral mucositis. It is anticipated that other clinical uses will be considered to expand upon the initial indications being studied.

Stage of Development

The FDA approved EpiCept’s Investigational New Drug (IND) application for EpiCept MP/DP in July 2001, and the Company completed a Phase IIa clinical trial on dental pain subjects in Europe in April 2002. Preliminary results have indicated that the product is well tolerated and provided a longer duration of pain relief compared to lidocaine by itself. Although this product candidate is not currently in active development, EpiCept intends to continue dose ranging and dose optimization trials in the future.